Literature DB >> 34207581

Bilirubin: A Promising Therapy for Parkinson's Disease.

Sri Jayanti1,2,3, Rita Moretti4, Claudio Tiribelli1, Silvia Gazzin1.   

Abstract

Following the increase in life expectancy, the prevalence of Parkinson's disease (PD) as the most common movement disorder is expected to rise. Despite the incredibly huge efforts in research to find the definitive biomarker, to date, the diagnosis of PD still relies mainly upon clinical symptoms. A wide range of treatments is available for PD, mainly alleviating the clinical symptoms. However, none of these current therapies can stop or even slow down the disease evolution. Hence, disease-modifying treatment is still a paramount unmet medical need. On the other side, bilirubin and its enzymatic machinery and precursors have offered potential benefits by targeting multiple mechanisms in chronic diseases, including PD. Nevertheless, only limited discussions are available in the context of neurological conditions, particularly in PD. Therefore, in this review, we profoundly discuss this topic to understand bilirubin's therapeutical potential in PD.

Entities:  

Keywords:  Parkinson’s disease; bilirubin; disease-modifying therapy; yellow players

Year:  2021        PMID: 34207581     DOI: 10.3390/ijms22126223

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  1 in total

1.  Clinical and Biological Factors Are Associated with Treatment-Resistant Depression.

Authors:  Massimiliano Buoli; Enrico Capuzzi; Alice Caldiroli; Alessandro Ceresa; Cecilia Maria Esposito; Cristina Posio; Anna Maria Auxilia; Martina Capellazzi; Ilaria Tagliabue; Teresa Surace; Francesca Legnani; Luisa Cirella; Martina Di Paolo; Guido Nosari; Francesco Zanelli Quarantini; Massimo Clerici; Fabrizia Colmegna; Antonios Dakanalis
Journal:  Behav Sci (Basel)       Date:  2022-02-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.